Cytotoxic effect of lapatinib is restricted to human papillomavirus-positive head and neck squamous cell carcinoma cell lines

References

• BernierJBentzenSMVermorkenJBMolecular therapy in head and neck oncologyNat Rev Clin Oncol20096526627719390553
   PubMed Web of Science ®Google Scholar
• VermorkenJBMedical treatment in head and neck cancerAnn Oncol200516Suppl 2ii258ii26415958469
   PubMed Web of Science ®Google Scholar
• ChaturvediAKEngelsEAAndersonWFGillisonMLIncidence trends for human papillomavirus-related and -unrelated oral squamous cell carcinomas in the United StatesJ Clin Oncol200826461261918235120
   PubMed Web of Science ®Google Scholar
• KongCSNarasimhanBCaoHThe relationship between human papillomavirus status and other molecular prognostic markers in head and neck squamous cell carcinomasInt J Radiat Oncol Biol Phys200974255356119427557
   PubMed Web of Science ®Google Scholar
• KimpleRJSmithMABlitzerGCEnhanced radiation sensitivity in HPV-positive head and neck cancerCancer Res201373154791480023749640
   PubMed Web of Science ®Google Scholar
• RieckmannTTribiusSGrobTJHNSCC cell lines positive for HPV and p16 possess higher cellular radiosensitivity due to an impaired DSB repair capacityRadiother Oncol2013107224224623602369
   PubMed Web of Science ®Google Scholar
• YardenYThe EGFR family and its ligands in human cancer: signalling mechanisms and therapeutic opportunitiesEur J Cancer2001373811342194
   PubMed Web of Science ®Google Scholar
• KimSGrandisJRRinaldoATakesRPFerlitoAEmerging perspectives in epidermal growth factor receptor targeting in head and neck cancerHead Neck200830566767418383530
   PubMed Web of Science ®Google Scholar
• CavalotAMartoneTRoggeroNBrondinoGPaganoMCortesinaGPrognostic impact of HER-2/neu expression on squamous head and neck carcinomasHead Neck200729765566417315173
   PubMed Web of Science ®Google Scholar
• TemamSKawaguchiHEl-NaggarAKEpidermal growth factor receptor copy number alterations correlate with poor clinical outcome in patients with head and neck squamous cancerJ Clin Oncol200725162164217017538160
   PubMed Web of Science ®Google Scholar
• LaimerKSpizzoGGastlGHigh EGFR expression predicts poor prognosis in patients with squamous cell carcinoma of the oral cavity and oropharynx: a TMA-based immunohistochemical analysisOral Oncol200743219319816854613
   PubMed Web of Science ®Google Scholar
• ChungCHElyKMcGavranLIncreased epidermal growth factor receptor gene copy number is associated with poor prognosis in head and neck squamous cell carcinomasJ Clin Oncol200624254170417616943533
   PubMed Web of Science ®Google Scholar
• KumarBCordellKGLeeJSEGFR, p16, HPV Titer, Bcl-xL and p53, sex, and smoking as indicators of response to therapy and survival in oropharyngeal cancerJ Clin Oncol200826193128313718474878
   PubMed Web of Science ®Google Scholar
• BonnerJAHarariPMGiraltJRadiotherapy plus cetuximab for squamous-cell carcinoma of the head and neckN Engl J Med2006354656757816467544
   PubMed Web of Science ®Google Scholar
• CohenMHJohnsonJRChenY-FSridharaRPazdurRFDA drug approval summary: erlotinib (Tarceva) tabletsOncologist200510746146616079312
   PubMed Web of Science ®Google Scholar
• CohenMHWilliamsGASridharaRUnited States food and drug administration drug approval summary: Gefitinib (ZD1839; Iressa) tabletsClin Cancer Res20041041212121814977817
   PubMed Web of Science ®Google Scholar
• KondoNTsukudaMIshiguroYAntitumor effects of lapatinib (GW572016), a dual inhibitor of EGFR and HER-2, in combination with cisplatin or paclitaxel on head and neck squamous cell carcinomaOncol Rep201023495796320204279
   PubMed Web of Science ®Google Scholar
• ErjalaKSundvallMJunttilaTTSignaling via ErbB2 and ErbB3 associates with resistance and epidermal growth factor receptor (EGFR) amplification with sensitivity to EGFR inhibitor gefitinib in head and neck squamous cell carcinoma cellsClin Cancer Res200612134103411116818711
   PubMed Web of Science ®Google Scholar
• RusnakDWAffleckKCockerillSGThe characterization of novel, dual ErbB-2/EGFR, tyrosine kinase inhibitors potential therapy for cancerCancer Res200161197196720311585755
   PubMed Web of Science ®Google Scholar
• GeyerCEForsterJLindquistDLapatinib plus capecitabine for HER2-positive advanced breast cancerN Engl J Med2006355262733274317192538
   PubMed Web of Science ®Google Scholar
• HarringtonKJEl-HariryIAHolfordCSPhase I study of lapatinib in combination with chemoradiation in patients with locally advanced squamous cell carcinoma of the head and neckJ Clin Oncol20092771100110719171712
   PubMed Web of Science ®Google Scholar
• KimpleRJHortonJKLivasyCAPhase I study and biomarker analysis of lapatinib and concurrent radiation for locally advanced breast cancerOncologist201217121496150323006498
   PubMed Web of Science ®Google Scholar
• HarringtonKBerrierARobinsonMRandomised Phase II study of oral lapatinib combined with chemoradiotherapy in patients with advanced squamous cell carcinoma of the head and neck: rationale for future randomised trials in human papilloma virus-negative diseaseEur J Cancer20134971609161823265705
   PubMed Web of Science ®Google Scholar
• PrétetJLJacquardACCarcopinoXEDITH Study GroupHuman papillomavirus (HPV) genotype distribution in invasive cervical cancers in France: EDITH studyInt J Cancer2008122242843217893882
   PubMed Web of Science ®Google Scholar
• WoodworthCDDiefendorfLPJetteDFInhibition of the epidermal growth factor receptor by erlotinib prevents immortalization of human cervical cells by Human Papillomavirus type 16Virology20114211192721982220
   PubMed Web of Science ®Google Scholar
• ChinnaiyanPHuangSVallabhaneniGMechanisms of enhanced radiation response following epidermal growth factor receptor signaling inhibition by erlotinib (Tarceva)Cancer Res20056583328333515833866
   PubMed Web of Science ®Google Scholar
• ZhouHKimY-SPeletierAMcCallWEarpHSSartorCIEffects of the EGFR/HER2 kinase inhibitor GW572016 on EGFR- and HER2-overexpressing breast cancer cell line proliferation, radiosensitization, and resistanceInt J Radiat Oncol Biol Phys200458234435214751502
   PubMed Web of Science ®Google Scholar
• SambadeMJCampJTKimpleRJSartorCIShieldsJMMechanism of lapatinib-mediated radiosensitization of breast cancer cells is primarily by inhibition of the Raf.MEK.ERK mitogen-activated protein kinase cascade and radiosensitization of lapatinib-resistant cells restored by direct inhibition of MEKRadiother Oncol200993363964419853943
   PubMed Web of Science ®Google Scholar
• VermorkenJBStöhlmacher-WilliamsJDavidenkoICisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trialLancet Oncol201314869771023746666
   PubMed Web of Science ®Google Scholar
• GiraltJFortinAMesiaRA phase II, randomized trial (CONCERT-1) of chemoradiotherapy (CRT) with or without panitumumab (pmab) in patients (pts) with unresected, locally advanced squamous cell carcinoma of the head and neck (LASCCHN)J Clin Oncol201230suppl abstr 5502 Available from: http://meetinglibrary.asco.org/content/93724-114Accessed April 25, 2014
   Google Scholar
• PlastarasJPKimSHLiuYYCell cycle–dependent and schedule-dependent antitumor effects of sorafenib combined with radiationCancer Res200767199443945417909054
   PubMed Web of Science ®Google Scholar
• RusnakDWAlligoodKJMullinRJAssessment of epidermal growth factor receptor (EGFR, ErbB1) and HER2 (ErbB2) protein expression levels and response to lapatinib (Tykerb, GW572016) in an expanded panel of human normal and tumour cell linesCell Prolif200740458059417635524
   PubMed Web of Science ®Google Scholar
• SpangleJMMungerKThe HPV16 E6 oncoprotein causes prolonged receptor protein tyrosine kinase signaling and enhances internalization of phosphorylated receptor speciesPLoS Pathog201393e100323723516367
   PubMed Web of Science ®Google Scholar
• StraightSWHermanBMcCanceDJThe E5 oncoprotein of human papillomavirus type 16 inhibits the acidification of endosomes in human keratinocytesJ Virol1995695318531927707548
   PubMed Web of Science ®Google Scholar
• KrauseMGurtnerKDeuseYBaumannMHeterogeneity of tumour response to combined radiotherapy and EGFR inhibitors: differences between antibodies and TK inhibitorsInt J Radiat Biol2009851194395419895271
   PubMed Web of Science ®Google Scholar
• ThatcherNChangAParikhPGefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)Lancet200536694961527153716257339
   PubMed Web of Science ®Google Scholar
• ShepherdFARodrigues PereiraJCiuleanuTNational Cancer Institute of Canada Clinical Trials GroupErlotinib in previously treated non-small-cell lung cancerN Engl J Med2005353212313216014882
   PubMed Web of Science ®Google Scholar
• SantinADSillMWMcMeekinDSPhase II trial of cetuximab in the treatment of persistent or recurrent squamous or non-squamous cell carcinoma of the cervix: a Gynecologic Oncology Group studyGynecol Oncol2011122349550021684583
   PubMed Web of Science ®Google Scholar
• FarleyJSillMWBirrerMPhase II study of cisplatin plus cetuximab in advanced, recurrent, and previously treated cancers of the cervix and evaluation of epidermal growth factor receptor immunohistochemical expression: a Gynecologic Oncology Group studyGynecol Oncol2011121230330821329967
   PubMed Web of Science ®Google Scholar
• KurtzJEHardy-BessardACDeslandresMCetuximab, topotecan and cisplatin for the treatment of advanced cervical cancer: a phase II GINECO trialGynecol Oncol20091131162019232434
   PubMed Web of Science ®Google Scholar
• BourhisJRiveraFMesiaRPhase I/II study of cetuximab in combination with cisplatin or carboplatin and fluorouracil in patients with recurrent or metastatic squamous cell carcinoma of the head and neckJ Clin Oncol200624182866287216717293
   PubMed Web of Science ®Google Scholar
• MerlanoMRussiEBenassoMCisplatin-based chemoradiation plus cetuximab in locally advanced head and neck cancer: a phase II clinical studyAnn Oncol201122371271720810547
   PubMed Web of Science ®Google Scholar
• BaselgaJTrigoJMBourhisJPhase II multicenter study of the antiepidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients with platinum-refractory metastatic and/or recurrent squamous cell carcinoma of the head and neckJ Clin Oncol200523245568557716009950
   PubMed Web of Science ®Google Scholar
• BurtnessBGoldwasserMAFloodWMattarBForastiereAAPhase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group studyJ Clin Oncol200523348646865416314626
   PubMed Web of Science ®Google Scholar
• VermorkenJBMesiaRRiveraFPlatinum-based chemotherapy plus cetuximab in head and neck cancerN Engl J Med2008359111116112718784101
   PubMed Web of Science ®Google Scholar
• GoncalvesAFabbroMLhomméCA phase II trial to evaluate gefitinib as second- or third-line treatment in patients with recurring locoregionally advanced or metastatic cervical cancerGynecol Oncol20081081424617980406
   PubMed Web of Science ®Google Scholar
• ChenCKaneMSongJPhase I trial of gefitinib in combination with radiation or chemoradiation for patients with locally advanced squamous cell head and neck cancerJ Clin Oncol200725314880488617971583
   PubMed Web of Science ®Google Scholar
• PerezCASongHRaezLEPhase II study of gefitinib adaptive dose escalation to skin toxicity in recurrent or metastatic squamous cell carcinoma of the head and neckOral Oncol201248988789222513208
   PubMed Web of Science ®Google Scholar
• GregoireVHamoirMChenCGefitinib plus cisplatin and radiotherapy in previously untreated head and neck squamous cell carcinoma: a phase II, randomized, double-blind, placebo-controlled studyRadiother Oncol20111001626921821303
   PubMed Web of Science ®Google Scholar
• CohenEEHarafDJKunnavakkamREpidermal growth factor receptor inhibitor gefitinib added to chemoradiotherapy in locally advanced head and neck cancerJ Clin Oncol201028203336334320498391
   PubMed Web of Science ®Google Scholar
• Nogueira-RodriguesAdo CarmoCCViegasCPhase I trial of erlotinib combined with cisplatin and radiotherapy for patients with locally advanced cervical squamous cell cancerClin Cancer Res200814196324632918829516
   PubMed Web of Science ®Google Scholar
• SchilderRJSillMWLeeY-CMannelRA phase II trial of erlotinib in recurrent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group StudyInt J Gynecol Cancer200919592993319574787
   PubMed Web of Science ®Google Scholar
• RusthovenKEFeigenbergSJRabenDInitial results of a Phase I dose-escalation trial of concurrent and maintenance erlotinib and reirradiation for recurrent and new primary head-and-neck cancerInt J Radiat Oncol Biol Phys20107841020102520231078
   PubMed Web of Science ®Google Scholar
• Arias de la VegaFContrerasJde Las HerasMMembers of GICOR (Grupo de Investigación Clínica en Oncología Radioterápica) GroupErlotinib and chemoradiation in patients with surgically resected locally advanced squamous cell carcinoma of the head and neck: a GICOR phase I trialAnn Oncol20122341005100921778302
   PubMed Web of Science ®Google Scholar
• SoulieresDSenzerNNVokesEEHidalgoMAgarwalaSSSiuLLMulticenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neckJ Clin Oncol2004221778514701768
   PubMed Web of Science ®Google Scholar
• HerchenhornDDiasFLViegasCMPhase I/II study of erlotinib combined with cisplatin and radiotherapy in patients with locally advanced squamous cell carcinoma of the head and neckInt J Radiat Oncol Biol Phys201078369670220421154
   PubMed Web of Science ®Google Scholar
• Del CampoJMHittRSebastianPEffects of lapatinib mono-therapy: results of a randomised phase II study in therapy-naive patients with locally advanced squamous cell carcinoma of the head and neckBr J Cancer2011105561862721829197
   PubMed Web of Science ®Google Scholar